1386 URINARY RETENTION FOLLOWING ANTIMUSCARINICS IN PATIENTS WITH BPH IN REAL LIFE PRACTICE - A NATION-WIDE DATABASE STUDY

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperlasia: Medical and Hormonal Therapy1 Apr 20131386 URINARY RETENTION FOLLOWING ANTIMUSCARINICS IN PATIENTS WITH BPH IN REAL LIFE PRACTICE - A NATION-WIDE DATABASE STUDY Eric Yi-Hsiu Huang, Chih-Chieh Lin, Hsiao-Jen Chung, Jian-Ping Lin, Alex T.L. Lin, and Kuang-Kuo Chen Eric Yi-Hsiu HuangEric Yi-Hsiu Huang Taipei, Taiwan More articles by this author , Chih-Chieh LinChih-Chieh Lin Taipei, Taiwan More articles by this author , Hsiao-Jen ChungHsiao-Jen Chung Taipei, Taiwan More articles by this author , Jian-Ping LinJian-Ping Lin Taipei, Taiwan More articles by this author , Alex T.L. LinAlex T.L. Lin Taipei, Taiwan More articles by this author , and Kuang-Kuo ChenKuang-Kuo Chen Taipei, Taiwan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2740AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Urinary retention (UR) is the main concern of using antimuscarinics in men with benign prostatic hyperplasia (BPH) presenting storage symptoms. Most clinical trials reported less than 1% UR rate. However, there is little information in real life clinical practice. We investigated the risks of UR following antimuscarinics in men with clinical diagnosis of BPH in real life practice by analyzing a nation-wide database. METHODS A urology dataset including 3,433,230 individuals was selected from the National Health Insurance Research Database (NHIRD) of Taiwan for the year 2006 to 2010. Their claim data was used for the study. Male patients more than 40 years old with a clinical diagnosis of BPH (ICD-9-CM code 600.0) and the use of available antimuscarinics (tolterodine, solifenacin, trospium, oxybutynin, propiverine) in Taiwan for more than 2 weeks were enrolled. All the enrolled patients used only one category of medication throughout the study period without switching (Group A: antimuscarinics only or Group B: antimuscarinics plus alpha-blockers). Patients receiving procedures that might cause UR such as intravesical therapy, urodynamic study and prostate biopsy during antimuscarinics treatment were excluded. UR was identified by the coding of urinary catheterization in the claim data during the medication period. The UR rate between Group A and Group B was compared. The association of UR with age was also explored. RESULTS The overall incidence of UR in this study cohort (n=27,461) was 2.37%. The UR rates for Group A (n=10,126) and Group B (n=16,935) were 2.5% and 2.3%, respectively without a significant difference (p=0.37). UR rate is increased with age. The UR rate for both groups was similar from 40 to 90 years and higher thereafter for Group A. (figure). CONCLUSIONS In real life practice, UR rate following antimuscarinics in patients with BPH is higher than reported in most clinical trials. Patients using alpha blocker plus antimuscarinics have similar UR rate as using antimuscarinics alone. Besides, age is an important risk factor for UR. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e567 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Eric Yi-Hsiu Huang Taipei, Taiwan More articles by this author Chih-Chieh Lin Taipei, Taiwan More articles by this author Hsiao-Jen Chung Taipei, Taiwan More articles by this author Jian-Ping Lin Taipei, Taiwan More articles by this author Alex T.L. Lin Taipei, Taiwan More articles by this author Kuang-Kuo Chen Taipei, Taiwan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...